AIM ImmunoTech advances Phase 2 DURIPANC trial of Ampligen plus AstraZeneca’s Imfinzi in pancreatic cancer
AIM•Phase 2 DURIPANC trial update
AIM ImmunoTech highlighted its ongoing Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s durvalumab as maintenance therapy in pancreatic cancer.
No new trial results were reported; primary endpoint analyses, biomarker readouts, and overall survival follow-up are expected in the future.
The study aims to show Ampligen can shift immunosuppressive tumors toward greater responsiveness to checkpoint inhibitors, supporting a potential pivotal program.
